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Abstract 
Understanding regulation of mitochondrial DNA (mtDNA) expression is of considerable 
interest as mitochondrial dysfunction is important in human pathology and ageing. Similar to 
the situation in bacteria, there is no compartmentalization between transcription and 
translation in mitochondria; hence, both processes are likely to have a direct molecular 
crosstalk. Accumulating evidence suggests that there are important mechanisms for regulation 
of mammalian mtDNA expression at the posttranscriptional level. Regulation of mRNA 
maturation, mRNA stability, translational coordination, ribosomal biogenesis and translation 
itself, all form the basis for controlling oxidative phosphorylation capacity. Consequently, a 
wide variety of inherited human mitochondrial diseases are caused by mutations of nuclear 
genes regulating various aspects of mitochondrial translation. Furthermore, mutations of 
mtDNA, associated with human disease and ageing, often affect tRNA genes critical for 
mitochondrial translation. Recent advances in molecular understanding of mitochondrial 
translation regulation will likely provide novel avenues for modulating mitochondrial 
function to treat human disease.   
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Introduction 
Expression of mtDNA is essential for biogenesis of the oxidative phosphorylation system 
(Larsson et al., 1998) and has a complex regulation at various levels, such as genome 
maintenance, transcription initiation, mRNA stability and translation (Falkenberg et al., 
2007). It is therefore not surprising that mutations of mtDNA are major causes of human 
disease, and are also heavily implicated in common forms of age-associated disease and the 
ageing process (Larsson, 2010). Human pathogenic mtDNA mutations were first described 
more than 25 years ago (Holt et al., 1988; Wallace et al., 1988) and it soon became apparent 
that many of them affect tRNA genes and thereby impair mitochondrial translation (Larsson 
and Clayton, 1995). Two mutations (m.1555A>G and m.1494C>T) in the 12S ribosomal 
RNA (rRNA) gene of mtDNA predispose to maternally inherited aminoglycoside-induced 
deafness (Prezant et al., 1993; Vandebona et al., 2009; Zhao et al., 2004). This shows that 
also side effects, of commonly used antibiotics, can originate in the mitochondrial translation 
system. During the last decade, it has become increasingly clear that also nuclear gene 
mutations can impair mitochondrial translation to cause human mitochondrial disease 
(Boczonadi and Horvath, 2014; Rötig, 2011). Furthermore, at least a subset of the many 
different types of mtDNA mutations found in ageing impair mitochondrial translation and 
these mutations undergo clonal expansion to create a mosaic pattern of respiratory chain 
deficiency in many different ageing mammalian tissues (Larsson, 2010).  
In this review, we will briefly describe the principles for transmission, maintenance 
and expression of mtDNA with special emphasis on mitochondrial translation. We will 
summarize the current knowledge of the regulation of mitochondrial translation, including 
novel insights into the biogenesis, structure and function of the mitoribosome.  
 
Transmission of mtDNA 
It is estimated that the human mtDNA mutation rate is at least an order of magnitude higher 
than the corresponding nuclear rate (Pakendorf and Stoneking, 2005). The transmission of 
mammalian mtDNA is asexual as it is strictly maternally inherited (Kaneda et al., 1995) and 
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does not undergo germ line recombination (Hagström et al., 2014). It has been predicted that 
any genome with these features would undergo what is known as the Muller’s ratchet effect, 
that is the accumulation of deleterious mutations over time that thereby causes a mutational 
meltdown (Muller, 1964). Mammals have several poorly understood mechanisms that 
counteract the Muller’s ratchet effect by decreasing the inheritance of mtDNA mutations 
between generations: (i) The bottleneck phenomenon is a mechanism that ensures that only a 
subset of the molecules in the mother’s mtDNA pool is transmitted to the offspring, which 
may lead to an mtDNA genotype shift in just a few generations (Hauswirth and Laipis, 1982). 
(ii) There is a purifying selection mechanism in the germ line that selectively removes the 
mtDNA mutations that cause amino acid substitutions (Stewart et al., 2008a; Stewart et al., 
2008b). (iii) There is a mechanism in developing embryos that selects against fetuses with 
high levels of pathogenic tRNA mutations (Freyer et al., 2012). (iv) High mutation levels in 
the female germ line decrease fertility (Ross et al., 2013). Accumulation of mtDNA mutations 
is heavily implicated in human ageing (Larsson, 2010) and recent experimental data suggest 
that low levels of maternally transmitted mtDNA mutations act synergistically with somatic 
mutagenesis to increase the total mtDNA mutation load and thus accelerate mammalian 
ageing (Ross et al., 2013). 
 
Maintenance and transcription of mtDNA 
The cellular mtDNA copy number varies by several orders of magnitude between tissues and 
is ~1 x 10
5 
in human oocytes (Chen et al., 1995) and ~3 x 10
3 
in human fibroblasts (Kukat et 
al., 2011). Recent work using super-resolution microscopy has shown that mammalian 
mtDNA is packaged into compacted nucleoid structures with a mean size of ~100 nm (Brown 
et al., 2011; Kukat et al., 2011). Most nucleoids seem to contain just a single copy of mtDNA 
and the main packaging factor is the high mobility group box domain protein called 
mitochondrial transcription factor A (TFAM) (Kukat et al., 2011). TFAM binds mtDNA 
cooperatively and can increase the flexibility of mtDNA and bend it to facilitate compaction 
(Fisher et al., 1992; Hallberg and Larsson, 2011; Ngo et al., 2011; 2014; Rubio-Cosials et al., 
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2011; Farge et al., 2012). Although TFAM is the main factor in the packaging of mtDNA, it 
is possible that other proteins also make significant contributions to the structure of the 
nucleoid (Kukat and Larsson, 2013).  
The two strands of mtDNA, which can be separated by buoyant-density 
ultracentrifugation, are, for historical reasons, called the heavy (H) and light (L) strands 
(Figure 1) (Battey and Clayton, 1978). Replication of mtDNA is often abortive and leads to 
the formation of a triple-stranded structure called the displacement (D-) loop, which contains 
a prematurely terminated nascent H strand. The D-loop region contains the origin for 
initiation of H (leading) strand mtDNA replication (OH), which requires an RNA primer 
formed by transcription at the light strand promoter (LSP). After mtDNA replication has been 
initiated, a poorly understood mechanism operating at the end of the D-loop will determine 
whether it will be abortive and lead to the formation of a D-loop structure or if it will proceed 
and result in the replication of the whole mtDNA molecule (Brown and Clayton, 2002). The 
replication of the lagging strand is initiated when leading-strand mtDNA replication is two-
thirds complete and the light-strand replication origin (OL) is activated (Clayton, 1982). Once 
it has been exposed in its single-stranded form, OL forms a stem-loop structure to which 
mitochondrial RNA polymerase (POLRMT) binds to produce the RNA primer necessary for 
initiation of lagging-strand mtDNA replication (Wanrooij et al., 2008; Wanrooij et al., 2012). 
There is currently no scientific consensus about the mode of mtDNA replication and in this 
regard several other models have been proposed (Lightowlers and Chrzanowska-Lightowlers, 
2012). 
 The mammalian mtDNA contains a dedicated main promoter for the transcription of 
each strand called the LSP and the H-strand promoter (HSP). The basal transcription initiation 
machinery consists of three proteins: POLRMT, TFAM and the mitochondrial transcription 
factor B2 (TFB2M) (Falkenberg et al., 2002; Shi et al., 2012). It is important to note that 
TFAM has dual roles because it is required for both transcription initiation (Shi et al., 2012) 
and the packaging of mtDNA into nucleoids (Bogenhagen et al., 2008; Ekstrand et al., 2004). 
There has been a long-standing hypothesis that the genes encoding rRNAs and mRNAs on the 
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H strand are transcribed from two distinct promoters called HSP1 and HSP2, respectively 
(Kruse et al., 1989).  According to this model transcription initiated at HSP1 is terminated 
immediately downstream of the rRNA genes as the mitochondrial transcription termination 
factor 1 (MTERF1) binds its target sequence in the tRNA
L(UUR) 
gene (Figure 1) (Kruse et al., 
1989; Martin et al., 2005). However, a recent knockout of the mouse Mterf1 gene has shown 
that the loss of MTERF1 does not affect rRNA gene expression, whereas the amount of 
antisense RNAs increases (Terzioglu et al., 2013). This result suggests that there is only one 
transcription unit for expression of H-strand genes that is regulated by one single HSP 
(Terzioglu et al., 2013). Contrary to previous assumptions, the main function of MTERF1 
seems to be to prevent transcription initiated at LSP from proceeding over the rRNA gene 
region to produce antisense transcripts. It is possible that such antisense transcripts may be 
disadvantageous as they may prevent proper folding of the 12S and 16S rRNAs. In addition, 
antisense transcription has been shown to interfere with LSP activity, possibly by 
transcriptional collision preventing re-initiation of transcription (Terzioglu et al., 2013). 
 
Mitochondrial RNA processing 
Transcription by POLRMT yields two long transcripts, one originating from LSP and the 
other from HSP. These two long transcripts are processed by the mitochondrial RNA-
processing machinery to release the individual tRNAs, rRNAs, and mRNAs (Figure 2). The 
processing is initiated on the tRNA sequences to release, according to the generally accepted 
tRNA punctuation model, the mRNAs and rRNAs that they intersperse (Figures 1 and 2) 
(Ojala et al., 1981). However, not all mRNAs are flanked by tRNA genes, as exemplified by 
ATP6-COIII, and ND5-Cyt b (Figure 1).  The pentatricopeptide repeat domain 2 (PTCD2) 
protein has been reported to be involved in processing of ND5–Cyt b (Xu et al., 2008), but it 
is otherwise unclear how mRNAs not flanked by tRNAs are processed.  
Evidence is accumulating to indicate that the early transcript processing takes place 
co-transcriptionally in small distinct speckles tentatively named mitochondrial RNA granules 
(MRGs) (Antonicka et al., 2013; Jourdain et al., 2013; Lee et al., 2013). The mitochondrial 
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5´-processing machinery in the form of the mitochondrial protein-only version of RNase P, 
consisting of three subunits (MRPP1-3), is found in these granules. In contrast, RNase Z, 
which constitutes the 3´-processing machinery of tRNAs, is not present in the MRGs 
(Jourdain et al., 2013). This fact, in combination with the primary structure of the 
intermediates that are formed upon knockdown of the 5´- and 3´- tRNA-processing machinery 
and the known inhibition of RNase Z by long 5´ leaders (Rossmanith et al., 1995; Levinger et 
al., 2001; Nashimoto et al., 1999) argues that the 5´ end of the tRNAs are processed first and 
the 3´ ends in a subsequent step (Figure 2). RNase Z in mammalian mitochondria consists of 
ELAC2 (Brzezniak et al., 2011; Rossmanith, 2011) possibly in complex with PTCD1 
(Sanchez et al., 2011). According to this model, the primary transcripts undergo an initial and 
partly co-transcriptional processing in the MRGs followed by a second round of processing 
outside the MRGs. 
Two of the three subunits of mitochondrial RNase P, MRPP1 and MRPP2, form a 
strong complex whereas MRPP3 binds the complex weakly and only under low-salt 
conditions in vitro (Holzmann et al., 2008). MRPP1 shows strong sequence homology to a 
family of tRNA N1-methyltransferases that methylate on position 9 in tRNAs and this m1A9 
or m1G9 modification is critical for obtaining a cloverleaf fold of mitochondrial tRNA
K
 
(Helm et al., 1998; Helm et al., 1999). Elegant single-molecule FRET experiments have 
shown an equilibrium between an extended non-physiological conformation and a cloverleaf 
conformation of mitochondrial tRNA
K
 (Voigts-Hoffmann et al., 2007). The reason for the 
extended non-physiological conformation is the possibility of a Watson-Crick base pairing 
between A9 and U64 in mitochondrial tRNA
K
. However, methylation of A9 renders the A9-
U64 Watson-Crick base pairing sterically impossible hence shifting the balance to a 
cloverleaf conformation. Interestingly, it was recently shown that the RNase P subcomplex of 
MRPP1-2 was necessary and sufficient for N1-methylation of both A and G (m1R9) of 
mitochondrial tRNAs (Vilardo et al., 2012). The methylation was shown to be rate limiting, 
so one can envision that the pre-tRNA structure of the primary transcript is bound by the 
MRPP1-2 subcomplex and that MRPP3 then comes in and trims the 5´ end while the tRNA is 
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being methylated on R9. Since the m1R9-methylation is likely to be crucial for cloverleaf 
formation for a majority of mitochondrial tRNAs, it is likely important that the tRNA gets this 
modification before it is released by the tRNA 5´- and 3´-processing machinery.  
The CCA in the acceptor stem of tRNAs is not encoded by mtDNA. It is instead 
added by the mitochondrial CCA-adding enzyme TRNT1 (Nagaike et al., 2001). Once the 
CCA sequence has been added to the 3´ end of the tRNA, it is no longer a substrate for 
RNAse Z because the CCA addition is an anti-determinant for RNase Z (Mohan et al., 1999). 
This arrangement makes unproductive cycling between TRNT1 and RNase Z impossible.  
 
Mitochondrial mRNA stability and polyadenylation 
The release of the 11 mtDNA-encoded mRNAs (Figure 1) occurs by RNA-processing events, 
as discussed above. Remarkably, the ND6 mRNA seems to be immediately competent for 
translation once liberated from the primary transcript and does not need any further 
maturation steps. The ND6 mRNA contains no 5´ untranslated region (UTR) and has a 
relatively short 3´ UTR that is not polyadenylated in humans (Temperley et al., 2010a) and 
mice (Ruzzenente et al., 2012). Also the other 10 mRNAs have no or strikingly short 5´ UTRs 
and often completely lack a 3´ UTR (Figure 1) (Montoya et al., 1981; Temperley et al., 
2010a) 
Two mRNAs, ND4L/ND4 and ATP8/ATP6, are bicistronic and each of them 
contains two open reading frames (ORFs) that are partly overlapping (Figure 1). It is possible 
that both ORFs are translated by a single interaction event between the mRNA and the 
ribosome, e.g. by first translating the 5´ ORF followed by backtracking and repositioning to 
translate the 3´ ORF. Alternatively, the mRNA may be released after translation of the 5´ 
ORF and a second interaction event facilitated by one as-yet-undefined internal ribosome 
entry site of the mRNA may allow translation of the 3´ ORF.  In this latter case, the mRNA 
would contain a long 5´ or 3´ UTR depending on which ORF is subject to translation.  
A 7-methylguanosine cap at the 5´-end of nucleus-encoded mRNAs is essential for 
translation in unicellular eukaryotes and metazoans (Cowling, 2010), but this modification is 
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lacking in the mtDNA-encoded mRNAs (Grohmann et al., 1978). All mRNAs except ND6 
contain short polyadenylation tails of ~45–50 nucleotides in length (Figure 1) (Ojala et al., 
1981b). A mitochondrial polyA polymerase (mtPAP) is required for polyadenylation of the 
mitochondrial mRNAs (Nagaike et al., 2005; Tomecki et al., 2004). Decreased 
polyadenylation affects the stability of a subset of mRNAs and leads to impaired 
mitochondrial translation and mitochondrial dysfunction (Nagaike et al., 2005; Tomecki et 
al., 2004).  The importance of mtPAP is further underscored by the finding that an autosomal 
recessive mutation in its gene leads to defective mRNA polyadenylation and clinical 
manifestations such as spastic ataxia and optic atrophy (Crosby et al., 2010). The 2´-
phosphodiesterase (PDE12) has been reported to remove polyA tails from mitochondrial 
mRNAs (Rorbach et al., 2011).  
The leucine-rich pentatricopeptide repeat (PPR)-containing (LRPPRC) protein 
belongs to the large family of PPR proteins that bind RNA and members of which are 
predominantly found in organelles  (Small and Peeters, 2000; Barkan et al., 2012). LRPPRC 
is mainly present in the mitochondrial matrix (Sterky et al., 2010), where it controls mRNA 
stability (Sasarman et al., 2010). Mice with knockout of Lrpprc and fruit flies with decreased 
expression of the fly ortholog of LRPPRC, called Bicoid stability factor (BSF or 
dmLRPPRC), have drastically reduced steady-state levels of mRNAs and drastically 
decreased polyadenylation of mRNAs and transcript processing defects (Bratic et al., 2011; 
Harmel et al., 2013; Ruzzenente et al., 2012). Interestingly, LRPPRC seems to stabilize a pool 
of translationally inactive transcripts and mitochondrial translation becomes chaotic and 
uncoordinated in the absence of LRPPRC in mammals and flies (Bratic et al., 2011; 
Ruzzenente et al., 2012). Consistent with the genetic studies, in vitro biochemistry has shown 
that LRPPRC suppresses RNA degradation by blocking the action of polynucleotide 
phosphorylase (PNPase) and promotes polyadenylation by stimulating the activity of mtPAP 
(Chujo et al., 2012). LRPPRC and the stem loop-interacting RNA-binding protein (SLIRP) 
form a stable complex (Ruzzenente et al., 2012; Sasarman et al., 2010). SLIRP becomes 
unstable and is degraded in the absence of LRPPRC and both proteins seem to act 
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synergistically to promote mRNA stability (Ruzzenente et al., 2012). Mutations in the gene 
encoding the LRPPRC protein cause the French Canadian type of Leigh syndrome (LSFC), a 
severe form of infantile neurodegeneration associated with deficient oxidative 
phosphorylation (Mootha et al., 2003; Mourier et al., 2014; Xu et al., 2004). The 
pathophysiology of the mitochondrial dysfunction in LSFC patients is not fully understood 
but likely involves defective regulation of mRNA stability, mRNA maturation and 
translation.  
 
Mitochondrial tRNA modification 
All mammalian mitochondrial tRNAs have rather high A and U content, and some tRNAs 
such as tRNA
S(AGY)
 have non-canonical secondary structures. Others, such as tRNA
D
 and 
tRNA
F
, lack the conventional stabilizing intramolecular interactions between the D-T loops. 
This inherent poor stability makes tRNAs in mammalian mitochondria more sensitive to 
processing and modification defects than, for example, bacterial tRNAs. There are more than 
200 disease-related mutations of tRNA genes in mtDNA and more than half of them can be 
regarded as definitely pathogenic (Yarham et al., 2010). The majority of these mutations are 
in positions subcritical to core tRNA function and their pathogenicity is the result of 
hindrance of the proper recognition by the mitochondrial tRNA-modification machinery.  
Modifications of tRNAs can be divided into two subgroups: those that are important 
for the overall structure and those that are important for decoding (i.e., codon-anticodon 
recognition). One of the important modifications for the overall structure of the mitochondrial 
tRNAs, m1A9 or m1G9, is introduced already when the 5´ processing of the tRNA occurs, as 
discussed above. However, the relative order of the ensuing modifications is currently 
unknown. To this end, the interdependence of different modifications should be studied using 
cell lines or mouse models with knockdowns or knockouts of tRNA-modification enzymes. In 
the following section, we shall focus on modifications that are related to human disease and 
that are located in the anticodon stem-loop.  
  10 
In several mitochondrial tRNAs, a wobble-position uridine is modified by a rather 
large adduct on the C5 atom of the uracil base. The modification, m5U (Figure 3), is needed 
for the correct codon-anticodon pairing for several mitochondrial tRNAs (Kurata et al., 2003). 
Specifically, the modification has been shown to stabilize U-G wobble pairing, at least when 
bound to a bacterial ribosome (Kurata et al., 2008). Taurine is the major part of this adduct 
and is connected to the uracil-base C5 through a methylene moiety (Figure 3). The taurine 
moiety is dietary (Suzuki et al., 2002), while the carbon source of the methylene moiety is 
unknown. The modification is unique for animal mitochondria, although there are similar 
adducts (cmnm
5
) in bacteria and yeast mitochondria (Figure 3). Whereas the mechanism of 
taurine modification of animal mitochondria tRNA is unknown, the mechanism of cmnm
5
 
modification (Figure 3) in bacteria and yeast mitochondria is well studied. In the bacterial 
case, a complex of two proteins (MnmE and MnmG) is sufficient and necessary to use a 
glycine and tetrahydrofolate derivative to make cmnm
5
. In yeast, it is clear that the presence 
of cmnm
5 
in mitochondrial tRNA requires MSS1 and MTO1 (Umeda et al., 2005), although 
the biochemical activity of this protein complex remains to be reconstituted in vitro. 
Homologs to MSS1 and MTO1 are also present in humans (hGTPBP3 and hMTO1), but it is 
unclear if a suitable tetrahydrofolate derivative is available as a co-substrate in human 
mitochondria. It is therefore uncertain, how the first step of the modification, which gives 
rises to the methylene moiety, is carried out. Defects in taurine modification are implicated in 
mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome 
(MELAS) as one causative mutation in tRNA
L(UUR)
 prevents recognition by the tRNA-taurine 
modification system (Kirino et al., 2005; Yasukawa et al., 2000). Out of the pool of taurine-
modified mitochondrial tRNAs, three (E, K and Q) are further modified with a thiolation of 
the 2-position on the wobble m5U to make m5s2U (Figure 3). A similar thiolation but then 
on a canonical U–base is catalyzed by thiouridylase MnmA in bacteria (Ikeuchi et al., 2006). 
MTU1 is the mitochondrial homolog of MnmA and knockdown of MTU1 diminished 
detectable s2U and reduced oxidative phosphorylation (Umeda et al., 2005). Point mutations 
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in MTU1 have been identified in patients with acute infantile liver failure. The identified 
point mutations rendered either amino acid changes in MTU1 or exon skipping and samples 
from the patients showed loss of 2-thiolation in the mitochondrial tRNAs for E, K and Q 
(Zeharia et al., 2009).  
Another enzyme involved in modifications in the anticodon stem-loop is 
pseudouridine synthase 1 (PUS1), which targets a large range of cellular RNAs, both 
cytosolic and mitochondrial. Specifically, U27 and U28 in several mitochondrial tRNAs (K, 
M, L, I and D) are pseudouridylated by PUS1 at either one or both positions. These 
pseudouridine modifications can potentially stabilize and preorder the anticodon stem loop in 
a confirmation amenable for the correct function on the ribosome (Agris, 2008). The 
structural-functional aspects of the active site of pseudouridine synthases are conserved in all 
classes of this large enzyme family (Ericsson et al., 2004) and characterized by a conserved 
aspartate residue. Different point mutations that are close in sequence or space to the active 
site in PUS1 have been found in mitochondrial myopathy lactic acidosis, and sideroblastic 
anemia (MLASA) patients (Fernandez-Vizarra et al., 2007; Patton et al., 2005).  
In the cytosol of eukaryotes, there are two main species of tRNA
M
 that are dedicated 
to either translation initiation or elongation. The mitochondrial genome, however, encodes 
only one species of tRNA
M
. Intriguingly, this single species of tRNA
M
 not only decodes AUG 
but also the canonical isoleucine codon AUA in initiation and elongation. Furthermore, 
mitochondrial tRNA
M
 also decodes AUU and AUC but only if they are the initiating codons, 
otherwise they are decoded as isoleucine as in the canonical code (Fearnley and Walker, 
1987). Specifically, the genes of ND1, ND2, ND3 and ND5 in human mitochondria utilize 
non-AUG start codons (Figure 1). To enable the proper codon-anticodon recognition of these 
non-canonical methionine codons, a formylation of the wobble C34 has been suggested and 
has, in the case of AUA, been shown to be needed (Bilbille et al., 2011; Moriya et al., 1994). 
The source of the formyl group and the responsible enzyme(s) for this critical modification 
remain unclear. 
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Aminoacyltransferase activity in mitochondria 
Just as in the eukaryotic cytosol and the bacterial cytosol, tRNAs in mitochondria are 
specifically charged with amino acids by aminoacyl-tRNA synthetases (aaRS). However, a 
few aspects of this charging process are idiosyncratic to mitochondria. There are 19 aaRSs in 
mitochondria, all encoded in the nuclear genome and, similarly to the cytosolic case in 
eukaryotes and bacteria, they can be divided into two classes (Class I and Class II) based on 
their primary sequences. There is no mitochondrial aaRS for Q. Instead, the aminoacylation 
of tRNA
Q
 follows an indirect pathway with misaminoacylation with E followed by a 
transamidation to Q by the heterotrimeric mitochondrial amidotransferase hGatCAB (Nagao 
et al., 2009). 
In general, it is very important that tRNAs are properly recognized by their cognate 
aaRSs and recurring mischarging of tRNAs severely reduces the overall translational fidelity. 
The mitochondrial aaRSs are unusual in their relative lack of discriminatory capacity and 
also, in some cases, disobeying the universal tRNA identity rules (Bonnefond et al., 2005; 
Giegé et al., 1998). It is likely that this is a consequence of the reduced T- and D-loop 
sequences of mitochondrial tRNAs. As an example, tRNA
Q
 is easily misacylated by the aaRS 
for S (Shimada et al., 2001). However, there appears to be a strong discriminatory mechanism 
in place against wrongly charged tRNAs in the binding step to elongation factor Tu (mtEFTu) 
(Nagao et al., 2007), although the molecular mechanism for this selection remains elusive. In 
fact, a multitude of mitochondrial diseases originates from mutations in mitochondrial aaRSs, 
but defects in aminoacylation can also be caused by mutations in the tRNA substrate such as 
those observed for tRNA
I
 and tRNA
K
 (Degoul et al., 1998; Sissler et al., 2004). 
As discussed above, mitochondria only have a single gene that encodes tRNA
M
 and a 
nucleus-encoded mitochondrial methionyl-tRNA formyltransferase (MTFMT) formylates a 
subset of tRNA
M
 for use in translation initiation whereas the non-formylated species is used 
for translation elongation (Tucker et al., 2011). Recessive mutations inactivating the MTFMT 
gene cause severe oxidative phosphorylation deficiency and Leigh syndrome in children 
(Tucker et al., 2011).  
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Mitoribosome biogenesis 
The mitoribosome biogenesis pathway can be divided into several distinct steps: (i) synthesis 
of 12S and 16S rRNA by transcription of mtDNA; (ii) nuclear gene expression to produce the 
mitoribosomal proteins of the small (MRPS) and large (MRPL) subunit, including possible 
posttranslational modifications of some of these proteins; (iii) post-transcriptional 
modification of the rRNAs by methylation, 2´-O-ribose methylation and pseudouridylation of 
specific residues; (iv) assembly of 16S rRNA and MRPL proteins to form the large subunit 
(LSU) of the mitoribosome; (v) assembly of 12S rRNA and MRPS proteins to form the small 
subunit (SSU) of the mitoribosome; and (vi) assembly of the mature SSU and LSU to 
functional mitoribosomes. It should be noted that several of these steps may partly coincide as 
some MRPs likely assemble with the rRNAs already during the transcription process 
(Bogenhagen et al., 2014).   
In nuclear and bacterial ribosome biogenesis, the initial rRNA processing and some 
modification steps are largely co-transcriptional (Henras et al., 2008; Kaczanowska and 
Rydén-Aulin, 2007). The rRNA methyltransferases RNMTL1, MRM1, and MRM2 were 
recently found in speckles that contained newly transcribed mitochondrial RNA (Lee et al., 
2013), supporting a co-transcriptional role in rRNA modification. Whether or not these 
structures are the same as the MRGs containing MRPP1-3 remains to be determined. In 
contrast, other rRNA modifications likely occur late in the biogenesis process and require the 
presence of rRNA/MRP assembly intermediates that are specifically recognized by rRNA- 
modification enzymes (Metodiev et al., 2009; Metodiev et al., 2014). 
Translating mitoribosomes in yeast are reported to be tethered to the inner 
mitochondrial membrane by MRP20, which is a homolog to bacterial L23 and human 
MRPL23.  In yeast, MRP20 is necessary for the formation of a ribosomal sub-complex with 
other proteins to achieve proper mitoribosome assembly and function (Kaur and Stuart, 
2011). This suggests that the LSU of the mitoribosome is assembled on the inner 
mitochondrial membrane (Figure 4 and 5).  
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Modifications of 16S rRNA and biogenesis of the LSU 
It was observed early that the large subunit of mammalian mitoribosomes is, compared to its 
bacterial and cytosolic counterparts, quite scarcely modified (Dubin, 1974). Three ribose 
methylations (human 16S numbering Gm
1145
; Um
1369
 Gm
1370
) have been reported from 
experiments in hamster cells (Baer and Dubin, 1981). In yeast, the enzymes responsible for 
the corresponding two first methylations in the large mitoribosomal rRNA (Gm
2270
; Um
2791
) 
have been identified as MRM1 (Pet56p) and MRM2, respectively (Sirum-Connolly and 
Mason, 1993; Pintard et al., 2002). Methylation by MRM1 is crucial for LSU (yeast 21S) 
stability and the mitochondrial function is compromised without this modification (Sirum-
Connolly and Mason, 1993). Likewise, MRM2 in yeast encodes an RNA-modifying enzyme 
(Um
2791
) and LSU production is slightly reduced upon MRM2 deletion (Pintard et al., 2002). 
Furthermore, the human homologs of MRM1 and MRM2 were recently shown to localize to 
mitochondria (Lee et al., 2013) but whether they carry out their presumed function (i.e., 2´-O-
ribose methylation of G1145 and U1369, respectively) has not yet been verified. However, 
the enzyme responsible for the third observed 2´-O-ribose methylation of 16S rRNA, 
Gm1370, was recently identified by the Bogenhagen group as RNMTL1, a methyltransferase 
of the SPOUT class (Lee et al., 2013).   
Pseudouridinylation was not observed in the initial studies of the large mitochondrial 
rRNA in hamster cells (Dubin and Taylor, 1978) although it could later be observed at U1397 
in mouse and human large mitochondrial rRNA using more sensitive methods (Ofengand and 
Bakin, 1997). The enzyme responsible for the corresponding modification in yeast 
mitochondria (Pus5) has a range of human homologs and it is currently unclear which, if any, 
of these perform the modification (Ansmant et al., 2000). 
 The MTERF3 protein is predicted to bind nucleic acids (Spåhr et al., 2010) and 
studies of Mterf3 knockout mice have shown that MTERF3 is essential for embryogenesis 
and that its loss leads to a dramatic upregulation of mitochondrial transcription accompanied 
by severe respiratory chain deficiency (Park et al., 2007). In a subsequent study, it was found 
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that knockout and downregulation of dmMTERF3 in fruit flies not only activates 
mitochondrial transcription, but also leads to impaired assembly of the LSU of the 
mitoribosome (Wredenberg et al., 2013). Similar to the findings in flies, the biogenesis of the 
LSU and mitochondrial translation are severely impaired in Mterf3 knockout mice 
(Wredenberg et al., 2013). RNA immunoprecipitation experiments have shown that both 
MTERF3 and dmMTERF3 specifically interacts with 16S rRNA in mice and in flies, 
respectively (Wredenberg et al., 2013). Whether MTERF3 interacts with a modifying enzyme 
to promote some specific type of rRNA modification or has another function in the biogenesis 
of the LSU is currently unknown. 
 The C7orf30 protein interacts with the LSU of the mitoribosome (Wanschers et al., 
2012) and promotes its biogenesis (Rorbach and Minczuk, 2012). The C7orf30 protein has 
been reported to interact with MRPL14 and downregulation of either of these two proteins 
leads to the formation of an LSU lacking several MRPLs that cannot be properly assembled 
into a monosome thereby resulting in severely impaired mitochondrial translation (Fung et al., 
2013). 
 
Modifications of 12S rRNA and biogenesis of the SSU 
Five modifications have been identified in 13S rRNA of the SSU of the hamster 
mitoribosome (Baer and Dubin, 1981) and these are likely conserved in all mammals. These 
modifications were mapped to the mouse mitochondrial ribosome sequences (Van Etten et al., 
1980) and included two adenine dimethylations (m
6
2A
937
 and m
6
2A
938
), one uracil methylation 
(m
5
U
425
) and two cytosine methylations (m
4
C
840
 and m
5
C
841 
or m
5
C
842
) (Baer and Dubin, 
1981).  
 The presence of two dimethylated adenines in a stem-loop structure at the 3´-end of 
the rRNA of the SSU is highly conserved in all domains of life (Shutt and Gray, 2006). In E. 
coli, the lack of the enzyme responsible for this modification, KsgA, leads to resistance to the 
aminoglycoside kasugamycin and growth retardation (Helser et al., 1971; Poldermans et al., 
1980). Mouse knockout studies show that loss of the Tfb1m gene leads to embryonic lethality 
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and complete absence of m
6
2A
937
and m
6
2A
938 
of the 12S rRNA in mouse mitochondria 
(Metodiev et al., 2009). Without these modifications the levels of the assembled SSU of the 
mitoribosome are drastically reduced and mitochondrial translation is severely impaired 
(Metodiev et al., 2009). 
The mitochondrial cytosine methyltransferase NSUN4 belongs to the same family of 
m5C-methyltransferases as the bacterial rRNA m5C-methyltransferases RsmB, RsmF and 
YccW (Cámara et al., 2011). In contrast to the bacterial homologs, NSUN4 lacks RNA 
binding domain extensions and instead it forms a stable complex with MTERF4 that targets 
the NSUN4/MTERF4 complex to the LSU of the mitoribosome (Cámara et al., 2011; Spåhr et 
al., 2012; Yakubovskaya et al., 2012). Knockout of either MTERF4 (Cámara et al., 2011) or 
NSUN4 (Metodiev et al., 2014) is embryonic lethal and appears to affect a late step in 
ribosomal biogenesis as both the SSU and LSU remain stable but do not interact to form a 
functional monosome. Recent sequencing of cDNA generated from bisulfite-treated mouse 
mitochondrial rRNA identified two cytosine methylations (m
4
C
840
 and m
5
C
842
) in 12S rRNA 
(Metodiev et al., 2014) corresponding to the modification sites previously identified in 
hamster mitochondria (Baer and Dubin, 1981). The m
4
C
840
 modification in mice has an E. 
coli homolog (m
4
C
1402
) that has been proposed to regulate translational precision through 
functional and conformational control of the P-site (Kimura and Suzuki, 2010). In Nsun4 
knockout mice, the m
5
C
842
 modification of 12S rRNA is absent whereas the m
4
C
840
 
modification is preserved (Metodiev et al., 2014). Remarkably, the knockout of MTERF4 
does not affect the m
5
C
842 
modification despite the fact that NSUN4 and MTERF4 form a 
very stable heterodimeric complex (Spåhr et al., 2012; Yakubovskaya et al., 2012). This has 
led to a model in which a free fraction of NSUN4 is proposed as responsible for the creation 
of the m
5
C
842 
modification of the 12S rRNA, whereas the NSUN4/MTERF4 complex has an 
essential role in the final assembly step of the monosome by binding the LSU to interact with 
the SSU (Metodiev et al., 2014). It is possible that the m
5
C
842 
modification of the 12S rRNA 
provides a quality control mark to ensure that only fully mature SSUs can interact with the 
LSU in the final assembly step of the monosome (Metodiev et al., 2014). It is important to 
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note that the adenine dimethylations (m
6
2A
937
and m
6
2A
938
)
 
of 12S rRNA are established 
independently of NSUN4 (Metodiev et al., 2014), which indicates that they may occur at an 
earlier stage of the biogenesis of the SSU. Also the protein encoded by C4orf14 has been 
reported to be necessary for SSU biogenesis, although the molecular mechanisms are not 
understood (He et al., 2012). 
 
The mammalian mitoribosome 
Mitoribosomes were found in mitochondrial isolates as early as the mid-’50s, but due to 
problems with proper mitochondrial isolation, their more detailed characterization required 
another ten years of methods’ development (O'Brien and Kalf, 1967).   
The complete mammalian mitoribosome (55S) is made up of the SSU (28S) and the 
LSU (39S). The SSU contains the 12S rRNA and more than 29 proteins, 15 of which do not 
have any obvious bacterial counterparts, whereas the LSU contains the 16S rRNA and 50 
proteins, 20 of which have no obvious bacterial counterpart (Sharma et al., 2003). This means 
that the mammalian mitochondrial ribosome contains a mass ratio of RNA to protein of about 
1:2, whereas the mass ratios of bacterial and the eukaryotic cytosolic ribosomes is about 2:1 
(Agrawal and Sharma, 2012). The mitoribosome has a proteobacterial origin, and during 
evolution, certain rRNA segments have been lost whereas the share of protein has increased 
and, as discussed below, ribosomal proteins have in some regions replaced evolutionarily lost 
rRNA segments.  
About half of the MRPs do not have any bacterial homolog identifiable by sequence 
alone, although it is probable that structural-functional aspects have been conserved in the 
absence of sequence homology. Nevertheless, it is clear that there are some unique proteins in 
the mitoribosome that have been acquired over the evolutionary period as a consequence of 
rRNA component loss. All mammalian MRPs are nuclear-encoded and most contain a 
mitochondrial localization sequence on the N-terminus (O'Brien, 2002).  
 
Structure description 
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The structure of the whole bovine mitoribosome has been determined by the Rajenda 
Agrawal group using cryo-EM at relatively low (13.5Å) resolution (Sharma et al., 2003) and 
this was for long the only available structural information on mammalian mitoribosomes. 
Very recently, however, the Agrawal work was complemented by the 4.9 Å resolution EM-
structure of the LSU of the pig mitoribosome by the of Nenad Ban group (Greber et al., 2014) 
(Figure 4). A pertinent feature of the EM-structures is that the rRNA is almost completely 
covered with protein. This is in stark contrast to the structures of the bacterial and the 
eukaryotic cytosolic ribosome, in which the protein is found in only small patches on the 
rRNA. Another difference from the bacterial and the eukaryotic cytosolic ribosomes is that 
there is considerable space between the MRPs on the mitochondrial ribosome with several 
passages available for bulk matrix solvent. This is one explanation for the fact that the 
sedimentation rate is lower for the mitoribosome (55S) than for E. coli (70S), although the 
mass of the mitochondrial ribosome is considerably larger at 2.7 MDa compared to 2.3 MDa 
for the E. coli ribosome.  
The LSU and SSU are connected by 15 inter-subunit bridges, of which only six are 
conserved to the bacterial homologs, whereas the rest differ in their chemical or spatial 
arrangement (Sharma et al., 2003; Kaushal et al, 2014). The mitoribosome subunits are 
mainly joined by protein-protein bridges in contrast to the bacterial counterpart, wherein most 
interconnection is by RNA-RNA bridging. Furthermore, the mRNAs that enter the SSU do so 
through an mRNA entrance lined with conserved mitochondrion-specific proteins (Sharma et 
al., 2003). In fact, in mammals it is unknown how the more-or-less leaderless mRNAs are 
recognized and transported to this gate. It has been shown that the addition of just a few 
nucleotides 5´ to the translation start practically abolishes the translation of mitochondrial 
mRNAs that are normally devoid of a 5´ UTR (Figure 1) (Christian and Spremulli, 2010). 
This is in stark contrast to the mRNA requirements of both bacterial and eukaryotic cytosolic 
ribosomes, and it points to fundamental differences in mitochondrial translation initiation in 
comparison with translation initiation in these systems. 
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 All of the translation products from the mammalian mitoribosome are membrane 
proteins and hence there are unique opportunities for adaptation and specialization of the 
mammalian mitoribosome for the task of translating membrane proteins. Indeed, it appears 
that the mitoribosome is normally bound to the inner membrane, removing the need for 
cycling between free and membrane-bound states, which occurs with the bacterial and 
eukaryotic cytosolic ribosomes (Liu and Spremulli, 2000). Furthermore, evidence is 
accumulating in favor of the claim that the polypeptides are inserted co-translationally into 
the inner membrane (Gruschke and Ott, 2010).  
From the EM-structures of the mitoribosome, it is apparent that on top of the 
conventional polypeptide exit site (PES), there is another channel (polypeptide accessible site 
[PAS]) some 25 Å from the PES where the newly formed peptide can also pass out from the 
ribosome (Greber et al., 2014; Sharma et al., 2003). Indeed, the human Oxa1L, which is 
important for insertion of proteins into the mitochondrial inner membrane has been reported 
to interact with the PAS but not with the conventional PES (Haque et al., 2010). It cannot be 
excluded that whether PAS or PES is used is translation-product dependent.  
From the higher resolution structure of the LSU from the Ban group, it was apparent 
that the ring of proteins MRPL23, MRPL47, MRPL22, MRPL24 and MRPL17 typically 
found around the PES in homologous ribosomes has an outer layer of proteins in the 
mammalian mitoribosome (Greber et al., 2014). Several of these outer layer proteins could be 
modeled into the electron density (Figure 4) and their interactions could be validated through 
crosslinking and mass spectrometry. Out of these novel outer-layer proteins, perhaps the most 
interesting is MRPL45, which shows strong homology to the membrane-associated TIM44. 
Furthermore, MRPL45 is ideally positioned as to act as a membrane anchor of LSU on the 
inner mitochondrial membrane to position the PES and PAS towards the membrane insertion 
machinery. In addition, MRPL45 forms a strong novel interaction with MRPL24 thereby 
replacing the rRNA that has the L24-fixating role in the bacterial ribosome. This is only one 
example of a situation in which the reductively evolved 16S rRNA has left large voids on the 
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surface of the LSU and the functionality of the reduced rRNA has been taken up by 
mitoribosomal proteins.  
On the other side of the LSU, at the central proturberance (CP), there are major 
differences compared to the bacterial ribosome. Although, this was clear already from the 
lower-resolution structure of the whole mitoribosome by the Agrawal group, the higher 
resolution in the newer LSU EM-structure permits the modeling of several proteins into the 
electron density of the CP. Here, MRPL52 takes on a prominent role, as it connects the 39S 
body with the CP with a 50-residue-long helix (Figure 4). This interaction replaces in part the 
5S RNA in bacterial and eukaryotic cytosolic ribosomes. Interestingly, a small piece of RNA 
is found to bind MRPL18 in a similar fashion as the -domain of 5S RNA bind L18 in the 
bacterial and eukaryotic cytosolic homologues (Figure 4). The identity of this piece of RNA 
is currently unknown. The recent 3.2 Å resolution EM structure of the yeast LSU also shows 
that the 5S rRNA is absent in the central protuberance of the LSU, but in contrast to the 
porcine LSU there is no other shorter RNA present at this location (Amunts et al., 2014). 
Instead, the central protuberance of the yeast LSU consists entirely of mitochondria-specific 
ribosomal proteins (Amunts et al., 2014). 
 
Mitochondrial translation 
Similar to bacterial and cytosolic ribosomes, mitochondrial translation is a multistep process 
requiring several different factors for initiation, elongation, termination and recycling  (Figure 
5). The mitochondrial translation process will only be briefly summarized here as a detailed 
review of this process has recently been published (Christian and Spremulli, 2012). 
Mitochondria contain two initiation factors (IF), denoted mtIF2 and mtIF3, whereas a 
homolog of the highly conserved IF1 is lacking. However, there is a 37 amino acid insertion 
domain in mtIF2 and this insertion was able to functionally replace IF1 in E. coli (Gaur et al., 
2008). Furthermore, the inserted peptide sequence does bind on the eubacterial ribosome at a 
site where normally the eubacterial IF1 would bind (Yassin et al., 2011). In the first step, 
mtIF3 binds the SSU and dissociates the monosome to release the LSU. The SSU mtIF3 
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complex then interacts with mtIF2, mRNA and tRNA carrying formylated methionine 
(tRNA
fM
). After the formation of this initiation complex, where tRNA
fM
 is bound to the start 
codon of the ORF of the mRNA, mtIF2 hydrolyzes its bound GTP to GDP and both initiation 
factors are released as the LSU binds to start translation (Figure 5).  
 The elongation phase ensues after the completion of the initiation, when mtEFTu, 
which forms a ternary complex with GTP and aminoacylated tRNA, enters the A-site of the 
mitoribosome. Base pairing of the tRNA anticodon with the codon contained in the mRNA 
leads to conversion of GTP to GDP and release of mtEFTu.  The ribosome then catalyzes 
peptide bond formation, whereby the peptide chain of the tRNA present at the P-site is 
transferred to the newly entered aminoacylated tRNA of the A-site, thus leading to 
prolongation of the peptide chain by one amino acid.  Next, binding of elongation factor G1 
(mtEFG1) catalyzes a translocation step that moves the tRNA with the attached peptide chain 
from the A- to the P-site simultaneously moving the deacylated tRNA from the P to the E site. 
The cycle is then repeated as mtEFTu again interacts with the ribosome to bring in the next 
aminoacylated tRNA.  
 At the end of the ORF, a stop codon is present and no aminoacylated tRNA can bind to 
continue peptide synthesis. Instead translation termination factors will interact with the stop 
codon to release the nascent peptide chain from the ribosome (Chrzanowska Lightowlers et 
al., 2011). In this context, it should be noted that the genetic code in mammalian 
mitochondria is somewhat different from the universal code and there are four different stop 
codons in mammalian mitochondria (UAA, UAG, AGA and AGG) (Anderson, et al., 1981). 
Remarkably, seven of the nine UAA stop codons are not fully encoded by mtDNA, but, 
instead, only generated after the addition of one or two A residues during polyadenylation 
(Anderson, et al., 1981). Mammalian mitochondria contain four translation termination factor 
homologs called mtRF1, mtRF1a, ICT1 and C12orf65 (Antonicka et al., 2010; Richter et al., 
2010; Soleimanpour-Lichaei et al., 2007), but the specific roles of each of these factors is at 
present not fully understood. Three of the factors mtRF1a, ICT1 and C12orf65 contain a 
classical GGQ sequence motif in their active sites that catalyzes hydrolysis of the peptidyl-
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tRNA bond. It has been reported that mtRF1a binds the nine UAA and the two UAG codons 
in mitochondrial transcripts to terminate translation (Soleimanpour-Lichaei et al., 2007). The 
non-standard stop codons AGA and AGG are present in the COI and ND6 transcripts, 
respectively (Figure 1), and are preceded by U in humans. Translation pausing at these 
codons followed by a -1 frame shift has been reported to create a UAG stop codon in both of 
these transcripts to allow mtRF1a to bind (Temperley et al., 2010b). However, recent 
homology modeling has questioned this concept and instead argues that ICT1 directly binds 
the AGA and AGG stop codons (Lind et al., 2013). After the completion of translation 
termination and release of the nascent peptide chain, the ribosome needs to be recycled 
through the disassembly of the two subunits and release of the mRNA. The ribosomal 
recycling factors 1 (mtRRF1) and 2 (mtRRF2, also known as elongation factor G2 or 
mtEFG2) are involved in this GTP-dependent process in mammalian mitochondria (Christian 
and Spremulli, 2012). 
 
The pleiotropic effects of impaired mitochondrial translation 
After the discovery of pathogenic single large deletions of human mtDNA (Holt et al., 1988), 
it soon became evident that one or more tRNA genes are always deleted (Mita et al., 1990). 
The affected patients are always heteroplasmic (Mita et al., 1990) and a fraction of >60% 
mutated mtDNA is needed to impair mitochondrial translation (Hayashi et al., 1991). 
Children with high levels of deleted mtDNA in multiple tissues typically develop a 
multisystem disease with symptoms such as sideroblastic anemia, pancreatic insufficiency, 
diabetes and renal failure, whereas adults often have a more limited tissue distribution of 
deleted mtDNA and develop a predominantly neuromuscular phenotype with symptoms such 
as progressive external ophthalmoplegia, myopathy, ataxia and deafness (Larsson and 
Clayton, 1995). Also heteroplasmic point mutations in tRNA genes are common causes of 
mitochondrial disease and today we know >200 such mutations (Blakely et al., 2013). 
Although the pathogenicity of half of these mutations can be questioned, there are still many 
mutations where overwhelming evidence shows that they cause human disease (Blakely et al., 
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2013).  The phenotypes caused by different tRNA point mutations vary tremendously and 
specific point mutations can cause remarkably different phenotypes in affected patients. One 
example is the m.3243A<G mutation in tRNA
L(UUR)
, which can cause MELAS syndrome 
(Goto et al., 1990), progressive external ophthalmoplegia (Moraes et al., 1993), and deafness 
and diabetes (van den Ouweland et al., 1992). Another example is the m.8344A>G mutation 
in tRNA
K
 (Shoffner et al., 1990), which in some individuals can cause a severe type of 
mitochondrial neurodegeneration called the myoclonus epilepsy with ragged-red muscle 
fibers syndrome (MERRF). However, in other individuals of the same pedigree, large lipomas 
of the neck as the only manifestation of the m.8344A>G mutation (Holme et al., 1993; 
Larsson et al., 1992). This phenotypic pleiotropism caused by pathogenic point mutations of 
mtDNA-encoded tRNA genes is largely unexplained and it has been speculated that the tissue 
distribution of mutant mtDNA and the nuclear genetic background of the mutation carrier are 
important determinants of the phenotype. 
 Given the extensive knowledge that has accumulated over the last 20 years about the 
extreme variability in clinical manifestations caused by mtDNA mutations affecting tRNA 
genes, it is perhaps not so surprising that also mutations in nuclear genes controlling 
mitochondrial translation have also been shown to result in a tremendous variability of 
clinical symptoms. A variety of mainly autosomal recessive mutations that impair 
mitochondrial translation are known and some examples of mutated genes include those that 
encode mRNA stability and polyadenylation factors (LRPPRC and mtPAP), tRNA-
modification enzymes (PUS1, MTU1 and MTO1), enzymes that aminoacylate tRNAs 
(DARS2, RARS2, EARS2, MARS2, FARS2, AARS2, YARS2, SARS2, HARS2 and 
LARS2), mitoribosomal proteins (MRPS16, MRPS22, MRPS28, MRPL3, MRPL12 and 
MRPL44), translation elongation and termination factors (mtEFTu, mtEFG1, mtEFTs and 
C12orf65), an enzyme for formylation of methionine (MTFMT) and translational activators 
of specific transcripts (TACO1) (Boczonadi and Horvath, 2014; Rötig, 2011). The resulting 
diseases are often lethal with a neonatal or infantile onset, and several recent reviews provide 
a detailed discussion about the severe clinical manifestations (Boczonadi and Horvath, 2014; 
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Rötig, 2011).  In several instances there is a relatively strong correlation between the mutated 
gene and the resulting clinical phenotypes, including neuropathological findings, as 
exemplified mutations in the different genes encoding the enzymes that aminoacylate tRNAs 
(Rötig, 2011).  
So why does impaired mitochondrial translation lead to such a variability of clinical 
manifestations? In some instances, this is due to poorly understood specific molecular events 
initiated by the mutated gene. In other cases, genetic modification of the resulting phenotype 
is likely to be an important determinant. It should be noted that genetic modification of the 
phenotype is also quite common in other types of genetic disease and even an archetypal 
inherited disease such as sickle cell anemia, caused by a homozygous mutation that 
exchanges a single amino acid in hemoglobin, show a substantial variation in the severity of 
symptoms between different patients (Lettre, 2012). The complexity of the mitochondrial 
translation machinery means that a mutated, dysfunctional component will have direct and 
indirect molecular interactions with a large number of other components. All of these 
interactions can be subject to genetic modifications and can thereby influence the overall 
impact on mitochondrial protein synthesis. Furthermore, tissue-specific differences in the 
abundance of different components of the mitochondrial translation machinery and tissue-
specific differences in the dependence on oxidative phosphorylation will also have major 
impact on the overall phenotype. 
 
Concluding remarks 
It is becoming increasingly clear that translational regulation is a major determinant of 
mammalian mtDNA expression, which is essential for oxidative phosphorylation. The 
complexity of the mitochondrial translation machinery is remarkable, given that the purpose 
is to synthesize only 13 proteins of the oxidative phosphorylation system. Translation of the 
mtDNA-encoded mRNAs is dependent on 24 mtDNA-encoded genes (2 rRNA and 22 
tRNAs) and at least one hundred nuclear-encoded genes that encode ribosomal proteins, 
translation factors, tRNA-modifying enzymes, ribosomal biogenesis factors, tRNA-aminoacyl 
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transferases and other factors. A large number of mainly autosomal recessive human diseases 
are caused by defective mitochondrial translation and affected patients often have neonatal or 
infantile onset often with very severe disease phenotypes. Furthermore, mutations of mtDNA 
often impair mitochondrial translation to cause a mosaic pattern of severe respiratory chain 
deficiency in disease and ageing. Within the next few years, we can expect a broader and 
more detailed molecular knowledge of the mitochondrial translation machinery. In this 
regard, an atomic structure of the mammalian mitoribosome would provide important 
mechanistic insights. It stands clear that a better understanding of the regulation of 
mitochondrial translation should enable the development of specific treatments aimed at 
ameliorating the mitochondrial dysfunction found in mitochondrial disease, age-associated 
diseases and ageing itself.   
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Legends to figures 
 
Figure 1 
The gene content of mammalian mtDNA and encoded mRNAs 
The mammalian mtDNA contains only one longer non-coding region, denoted the 
displacement (D-) loop region, which contains regulatory sequences needed for mtDNA 
replication and transcription. The mtDNA encodes 2 rRNAs (red boxes), 22 tRNAs (green 
boxes) and 11 mRNAs with 13 open reading frames (ORFs, blue boxes). The mRNAs contain 
no or very short 5´ non-coding sequences (yellow boxes) preceding the first translation 
initiation codon (AUA, AUU or AUG).  Furthermore, most mRNAs lack 3´ non-coding 
sequences (yellow boxes) between the stop codon (AGA, AGG, UAA and UAG) and the 
short poly A tail. Two of the mRNAs (ND4/ND4L and ATP6/ATP8) are bicistronic and each 
contains two partly overlapping ORFs. The structure of the human mRNAs are shown in the 
right panel.  
 
Figure 2  
Posttranscriptional maturation of mtDNA-encoded RNAs 
Each strand of mtDNA is transcribed as a long polycistronic transcript that is subsequently 
processed to release the individual mRNAs, tRNAs and rRNAs. The mitochondrial RNase P 
consists of three subunits (MRPP1-3) and cleaves the primary transcript at the 5´-end of 
tRNAs. MRPP1-2 are responsible for an N1-methylation of mitochondrial tRNAs. The 
tRNAs are released by cleavage at their 3´-ends by RNase Z (ELAC2).  Yellow dots indicate 
RNA modifications. 
 
Figure 3 
RNA modifications present in mitochondria 
Nucleobases with modifications that are found in mitochondrial RNA and discussed in the 
text.  The base modifications are highlighted with a lighter background. Cmnm
5
U is present 
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only in bacteria and yeast mitochondria but is shown for comparison to the mammalian 
mitochondrial taurine-based modifications. 
 
Figure 4 
Structure of the large subunit of the mammalian mitoribosome 
Rendered from the 4.9 Å EM-structure of the large subunit of the porcine mitoribosome 
(Greber et al., 2014). rRNA is colored in light-beige and ribosomal proteins that are not 
specifically denoted are colored in green. The RNA found to be bound to MRPL18 in the 
structure is denoted ‘RNA X’. 
 
Figure 5 
Biogenesis of the mammalian mitoribosomes and the translation cycle 
The biogenesis of the mitoribosome requires that the 12S and 16S rRNAs are modified and 
assembled together with the ribosomal proteins. The large subunit of the mitoribosome is 
believed to be anchored to the inner mitochondrial membrane and the translation cycle 
requires several factors for initiation, elongation and termination. The membrane anchoring of 
the mitoribosome is believed to facilitate insertion of newly synthesized proteins into the 
inner mitochondrial membrane. The recycling of the mitoribosome is not shown. 
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